- Home
- QSI vs MLYS Comparison
QSI vs MLYS Comparison
Compare QSI & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QSI | MLYS |
|---|---|---|
| Founded | 2013 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 273.7M | 3.1B |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | QSI | MLYS |
|---|---|---|
| Price | $1.32 | $37.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $2.63 | ★ $47.33 |
| AVG Volume (30 Days) | ★ 4.2M | 1.6M |
| Earning Date | 11-05-2025 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,177,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $159.68 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 40.20 | N/A |
| 52 Week Low | $0.95 | $8.24 |
| 52 Week High | $5.77 | $47.65 |
Technical Indicators
Market Signals| Indicator | QSI | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 46.07 | 44.26 |
| Support Level | $1.20 | $36.01 |
| Resistance Level | $1.32 | $38.23 |
| Average True Range (ATR) | 0.09 | 1.77 |
| MACD | 0.01 | 0.07 |
| Stochastic Oscillator | 38.89 | 42.59 |
Price Performance
Historical ComparisonAbout QSI Quantum-Si Incorporated
Quantum-Si Inc is a life sciences company focused on the development and commercialization of proteomics research tools. The company has designed and developed a hardware, consumable, and software solution to provide a solution for protein detection and analysis. It has developed a proprietary universal single-molecule detection platform that enables Next-Generation Protein Sequencing (NGPS), the ability to sequence proteins.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.